Physicians' Academy for Cardiovascular Education

Hypertension

Recently added learning

No clinical benefit from suspending ACEi/ARBs in hospitalized patients with COVID-19

3' education - Sep. 7, 2020 - Prof. Renato D. Lopes, MD, PhD

BP lowering should be considered irrespective of prior CVD or baseline SBP

3' education - Sep. 1, 2020 - Kazem Rahimi, MD
Lecture 1 out of 3

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - Apr. 19, 2020 - Prof. Jan Danser, PhD
Lecture 2 out of 3

A clinical perspective on COVID-19, ACE2 and RAAS inhibition

10' education - Apr. 18, 2020 - Prof. Murray Epstein, MD

Biochemical urine test to measure medical adherence in hypertension

5' education - Oct. 24, 2019 - Paris, France - Dan Lane

Decreased CV risk with an intervention targeting identified barriers to care

3' education - Aug. 31, 2019 - ESC 2019, Paris - Prof. J-D Schwalm

Community-wide salt restriction reduces blood pressure and incidence of hypertension

3' education - Sep. 2, 2019 - Paris, France - Prof. Jaime Miranda

RAAS inhibition in patients with kidney disease: Balancing the benefits and risks

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. Patrick Rossignol, MD - Online CME

New recommendations of the ESC/ESH Guidelines on the management of hypertension

3' education - Feb. 11, 2019 - Prof. Bryan Williams - London, UK

Get involved in May Measurement Month to increase awareness of elevated blood pressure

3' education - Feb. 6, 2019 - Prof. Neil Poulter - London, UK

Long term benefits of antihypertensive and cholesterol-lowering treatment in hypertension

10' education - Nov. 20, 2018 - Dr. Ajay Gupta - London, UK

Screening for high blood pressure globally

10' education - Nov. 20, 2018 - Dr. Thomas Beaney - London, Uk

Importance of hypertension in CVD prevention

10' education - June 12, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (1/3)

The cardiovascular challenge for primary care in diabetes

10' education - June 14, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

The future of renal denervation in the treatment of hypertension

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Michael Böhm, Homburg, Germany

Pharmacist intervention in black barbershop beats usual care at lowering BP

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Ronald Victor, MD - Los Angeles, CA, USA

New ACC/AHA hypertension guidelines empasize risk assessment

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Prof. Clyde Yancy - Chicago, IL, USA

Good BP measurement depends more on appropriate technique than on absence of staff

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Karen Johnson - Memphis, TN, USA

Target for BP lowering differs between Europe and USA

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Prof. Clyde Yancy - Chicago, IL, USA

Clinical outcomes and adverse effects comparable across various BP measurement methods in SPRINT

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Dr. Sripal Bangalore - NYU Langone, New York, NY, USA.

New ACC/AHA Hypertension Guidelines: stress on accuracy BP measurement method and lifestyle changes ánd a new target

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Paul Whelton, MD (Tulane University, New Orleans, LA, USA

BP lowering with endovascular baroreflex amplification in resistant hypertension: the CALM-FIM study

3' education - Aug. 29, 2017 - Dr. Wilko Spiering - UMCU

Take home messages of the ESC congress for better hypertension treatment

3' education - Aug. 29, 2017 - Dr. Clyde Jancy - Northwestern University, Feinberg University, Chicago, IL, VS

Well-conducted trial confirms principle that renal denervation can lower blood pressure

3' education - Aug. 29, 2017

NSAID ibuprofen increases blood pressure significantly more than other selective COX2 inhibitors

3' education - Aug. 28, 2017

E-counselling improves adherence in hypertensives

3' education - Mar. 21, 2017 - Dr. Rob Nolan, Toronto, ONT, Canada

Get involved in May Measurement Month!

3' education - Jan. 22, 2017 - London, United Kingdom - Prof. Neil R Poulter, MD (London, UK) - ISH President

How low to go with blood pressure: J-curve or not?

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Deepak L.Bhatt, MD, MPH (Boston, MA, USA)

To SPRINT or not to SPRINT to a lower blood pressure target?

10' education - Aug. 29, 2016 - ESC Rome, Italy - William C Cushman (Memphis, TN, USA) and Sverre E Kjeldsen (Oslo, Norway)

Understanding Diabetic Kidney Disease: What are the best options for clinical management?

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - Per-Henrik Groop, MD – University of Helsinki, Helsinki, Finland
##FULL_TITLE##

BP-lowering medication should not be used in normotensive primary prevention population at intermediate CV risk

10' education - May 10, 2016 - ACC 2016, Chicago, IL, USA - Eva Lonn (Hamilton, ONT, Canada)
##FULL_TITLE##

HOPE-3: Statin therapy works in everybody with intermediate-risk

3' education - Apr. 8, 2016 - Salim Yusuf MD, McMaster University, Hamilton, Ontario
##FULL_TITLE##

PARAMETER: heart failure agent to treat hypertension

3' education - Aug. 31, 2015 - ESC - Londen 2015 - Bryan Williams
##FULL_TITLE##

PARAMETER: heart failure agent to treat hypertension

3' education - Sep. 1, 2015 - ESC - Londen 2015 - Bryan Williams
##FULL_TITLE##

PATHWAY-2: which agent can best treat therapy resistant hypertension?

3' education - Aug. 31, 2015 - ESC - Londen 2015 - Bryan Williams
##FULL_TITLE##

PARADIGM-HF: Rationale, results & implications

3' education - Dec. 11, 2014 - Chicago, Il, USA VBWG - John J McMurray
##FULL_TITLE##

CV Risk management in Russia

3' education - Dec. 3, 2014 - Moscow - Prof Andrey Susekov
##FULL_TITLE##

Innovating hypertension: targeting the underlying disease process

3' education - Sep. 8, 2014 - Barcelona - Prof Bryan Williams
##FULL_TITLE##

Innovating hypertension management beyond current therapies: What are the opportunities?

10' education - Sep. 6, 2014 - Snapshot 2014 - Prof. Bryan Williams, UCL, London, United Kingdom
##FULL_TITLE##

Are new hypertension guidelines helpful for patients at high risk?

3' education - May 23, 2014 - CDMC Almaty - Dr Peter Meredith, Glasgow
##FULL_TITLE##

Improving BP measurement for better hypertension management

3' education - Apr. 25, 2014 - CDMC Almaty - Prof Luis Ruilope, Madrid, Spain
##FULL_TITLE##

New British guidelines and risk calculator on CV Risk (JBS3)

3' education - Apr. 7, 2014 - ACC 2014 - Prof John E Deanfield
##FULL_TITLE##

Update on therapy-resistant hypertension: Novel pharmacotherapy or renal denervation?

10' education - Sep. 14, 2013
##FULL_TITLE##

Therapy resistant hypertension: novel pharmacotherapy or renal denervation?

3' education - Sep. 10, 2013 - Amsterdam, August 31, 2013 - Luis Ruilope
##FULL_TITLE##

Blood Pressure: Does it matter how to lower it?

3' education - June 20, 2013 - CVRMC Kuala Lumpur - Prof. Peter Sever
##FULL_TITLE##

The unmet need for controlling hypertension

3' education - June 17, 2013 - VBWG San Francisco - Dr. Domenic Sica
##FULL_TITLE##

Preview on new hypertension guidelines

3' education - May 8, 2013 - CDMC Hanoi - Prof Michael A Weber
##FULL_TITLE##

New drugs and devices in development for hypertension

3' education - Apr. 18, 2013 - VBWG at ACC 2013 - Domenic Sica
##FULL_TITLE##

Renal denervation: New frontier in treating resistant hypertension

3' education - Dec. 11, 2012 - LA AHA 2012 - Dr Horst Sievert
##FULL_TITLE##

Managing blood pressure: choosing the right strategy to meet BP targets

3' education - Oct. 28, 2011
##FULL_TITLE##

RAS Blockade in the Real World: From Clinical Trial Data to Challenges in Daily Hypertension Management

3' education - Oct. 28, 2011
##FULL_TITLE##

RAS Blockade in hypertension

3' education - July 22, 2011
##FULL_TITLE##

Hypertension and diabetes

3' education - July 29, 2009

On demand 10" video

Lecture 1 out of 3

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - Apr. 19, 2020 - Prof. Jan Danser, PhD
Lecture 2 out of 3

A clinical perspective on COVID-19, ACE2 and RAAS inhibition

10' education - Apr. 18, 2020 - Prof. Murray Epstein, MD

RAAS inhibition in patients with kidney disease: Balancing the benefits and risks

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. Patrick Rossignol, MD - Online CME

Long term benefits of antihypertensive and cholesterol-lowering treatment in hypertension

10' education - Nov. 20, 2018 - Dr. Ajay Gupta - London, UK

Screening for high blood pressure globally

10' education - Nov. 20, 2018 - Dr. Thomas Beaney - London, Uk

Importance of hypertension in CVD prevention

10' education - June 12, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (1/3)

The cardiovascular challenge for primary care in diabetes

10' education - June 14, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

To SPRINT or not to SPRINT to a lower blood pressure target?

10' education - Aug. 29, 2016 - ESC Rome, Italy - William C Cushman (Memphis, TN, USA) and Sverre E Kjeldsen (Oslo, Norway)
##FULL_TITLE##

BP-lowering medication should not be used in normotensive primary prevention population at intermediate CV risk

10' education - May 10, 2016 - ACC 2016, Chicago, IL, USA - Eva Lonn (Hamilton, ONT, Canada)
##FULL_TITLE##

Innovating hypertension management beyond current therapies: What are the opportunities?

10' education - Sep. 6, 2014 - Snapshot 2014 - Prof. Bryan Williams, UCL, London, United Kingdom
##FULL_TITLE##

Update on therapy-resistant hypertension: Novel pharmacotherapy or renal denervation?

10' education - Sep. 14, 2013

No clinical benefit from suspending ACEi/ARBs in hospitalized patients with COVID-19

3' education - Sep. 7, 2020 - Prof. Renato D. Lopes, MD, PhD
BRACE CORONA was a randomized trial that tested two strategies in hospitalized patients with COVID-19 who were on ACEi or ARBs: Temporarily suspending or continuing ACEi/ARBs. Prof. Lopes discusses the results.

ESC 2020 BRACE CORONA was a randomized trial that tested two strategies in hospitalized patients with COVID-19 who were on ACEi or ARBs: Temporarily suspending or continuing ACEi/ARBs. Prof. Lopes discusses the results.

BP lowering should be considered irrespective of prior CVD or baseline SBP

3' education - Sep. 1, 2020 - Kazem Rahimi, MD
BP lowering  of 5 mm Hg results in 10% reduction of major CV events and is consistent whether individuals had a previous CVD or not, and is regardless of baseline SBP.

ESC 2020 A study including 48 RCTs demonstrated that lowering of each 5 mmHg SBP resulted in 10% reduction of major CV events, regardless of baseline SBP and CVD status.

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - Apr. 19, 2020 - Prof. Jan Danser, PhD
This presentation is part of a webinar on COVID-19, ACE2 and RAAS inhibition and focusses on the scientific data that is available on the ACE2 receptor and RAAS inhibitors.

This presentation is part of a webinar on COVID-19, ACE2 and RAAS inhibition and focusses on scientific data that is available on the ACE2 receptor and RAAS inhibitors.

A clinical perspective on COVID-19, ACE2 and RAAS inhibition

10' education - Apr. 18, 2020 - Prof. Murray Epstein, MD
As part of a webinar on COVID-19, ACE2 and RAASi, prof. Epstein presents what the clinical implications are of discontinuation of RAASi in COVID-19 patients and strongly recommends to continue use of these medications.

As part of a webinar on COVID-19, ACE2 and RAASi, prof. Epstein presents clinical implications of discontinuation of RAASi in COVID-19 patients and strongly recommends to continue use of these medications.

Biochemical urine test to measure medical adherence in hypertension

5' education - Oct. 24, 2019 - Paris, France - Dan Lane
Eline Groenland asks Dan Lane about his novel screening method using urine samples that can detect whether hypertensive patients take their drugs. This test may help to improve medical adherence.

CSI Paris Eline Groenland asks Dan Lane about his novel screening method using urine samples that can detect whether hypertensive patients take their drugs. This test may help to improve medical adherence.

Decreased CV risk with an intervention targeting identified barriers to care

3' education - Aug. 31, 2019 - ESC 2019, Paris - Prof. J-D Schwalm
In community-based studies in Colombia and Malaysia, HOPE-4 achieved reduced CV risk, better treatment adherence and healthier behavior with an intervention that targeted previously identified barriers to care.

ESC 2019 In community-based studies in Colombia and Malaysia, HOPE-4 achieved reduced CV risk, better treatment adherence and healthier behavior with an intervention that targeted previously identified barriers to care.

Community-wide salt restriction reduces blood pressure and incidence of hypertension

3' education - Sep. 2, 2019 - Paris, France - Prof. Jaime Miranda
A stepped-wedge cluster randomized controlled trial showed that a salt-substitution strategy in 6 villages in Peru lowered blood pressure and reduced incidence of hypertension by half.

ESC 2019 A stepped-wedge cluster randomized controlled trial showed that a salt-substitution strategy in 6 villages in Peru lowered blood pressure and reduced incidence of hypertension by half.

RAAS inhibition in patients with kidney disease: Balancing the benefits and risks

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. Patrick Rossignol, MD - Online CME
Although RAAS inhibition reduces proteinuria and hypertension in cardio-renal patients, it is associated with increased risk of hyperkalemia. Prof. Rossignol shares data on the addition of patiromer in patients using spironolactone for the mangement of CKD with resistant hypertension.

Although RAAS inhibition reduces proteinuria and hypertension in cardio-renal patients, it is associated with increased risk of hyperkalemia. Prof. Rossignol shares data on the addition of patiromer in patients using spironolactone for the management of CKD with resistant hypertension.

New recommendations of the ESC/ESH Guidelines on the management of hypertension

3' education - Feb. 11, 2019 - Prof. Bryan Williams - London, UK
Bryan Williams, co-chair of the 2018 ESC/ESH Hypertension Guidelines, lists the most important new recommendations. Furthermore, he comments on the discussion on differences between the European and American recommendations.

Bryan Williams, co-chair of the 2018 ESC/ESH Hypertension Guidelines, lists the most important new recommendations. Furthermore, he comments on the discussion on differences between the European and American recommendations.

Get involved in May Measurement Month to increase awareness of elevated blood pressure

3' education - Feb. 6, 2019 - Prof. Neil Poulter - London, UK
Neil Poulter stresses that, although high BP is considered a boring topic by some, it is crucial to be aware of it before it can be treated properly.

Neil Poulter stresses that, although high BP is considered a boring topic by some, it is crucial to be aware of it before it can be treated properly. You too can get involved in raising awareness.

Long term benefits of antihypertensive and cholesterol-lowering treatment in hypertension

10' education - Nov. 20, 2018 - Dr. Ajay Gupta - London, UK
Dr. Ajay Gupta investigated the long term effects of treatment with a calcium channel blocker-based regimen and a statin on mortality in patients with hypertension, and showed a legacy effect of the combined therapy.

ESC 2018 Dr. Ajay Gupta investigated the long term effects of treatment with a calcium channel blocker-based regimen and a statin on mortality in patients with hypertension, and showed a legacy effect of the combined therapy.

Screening for high blood pressure globally

10' education - Nov. 20, 2018 - Dr. Thomas Beaney - London, Uk
Across the world, one out of five people has hypertension. In this video dr. Thomas Beaney shares the first results of the May Measurement Month project, which aims to raise awareness of high blood pressure globally in prevention of CVD.

ESC 2018 Across the world, one out of five people has hypertension. In this video dr. Thomas Beaney shares the first results of the May Measurement Month project, which aims to raise awareness of high blood pressure globally in prevention of CVD.

Importance of hypertension in CVD prevention

Clinical updates in management of cardiovascular risk (3/4)

10' education - June 12, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME
Hypertension is one of the most established and major risk factors for CVD. Prof Hobbs gives an overview on the impact of hypertension on CV outcomes, how the diagnosis is made, on the benefits of therapy, and what the BP targets are.

Clinical updates in management of cardiovascular risk Hypertension is one of the most established and major risk factors for CVD. Prof Hobbs gives an overview on the impact of hypertension on CV outcomes, how the diagnosis is made, on the benefits of therapy, and what the BP targets are.

The cardiovascular challenge for primary care in diabetes

10' education - June 14, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME
Prof. Hobbs stresses  the importance of CVRM in primary care and how to manage this risk beyond glucose control.

Prof. Hobbs stresses the importance of CVRM in primary care and how to manage this risk beyond glucose control.

The future of renal denervation in the treatment of hypertension

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Michael Böhm, Homburg, Germany
After lack of sham-controlled trials, the SPYRAL program has started to test the efficacy of renal denervation in patients with uncontrolled hypertension. Two pilot studies with a sham controlled group in patients without and with medications are nearly finished.

VBWG at ACC 2018 After lack of sham-controlled trials, the SPYRAL program has started to test the efficacy of renal denervation in patients with uncontrolled hypertension. Two pilot studies with a sham controlled group in patients without and with medications are nearly finished.

Pharmacist intervention in black barbershop beats usual care at lowering BP

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Ronald Victor, MD - Los Angeles, CA, USA
Barbershops and pharmacists worked together to improve high BP in non-hispanic black men in Los Angeles County, a group with particularly high rates of uncontrolled hypertension. In a randomized design, a pharmacist intervention led to 27 mmHg drop over 6 months, vs. 9 mmHg in controls.

ACC 2018 Black barbershops and pharmacists worked together to improve high BP in non-hispanic black men. In a randomized design, a pharmacist intervention led to 27 mmHg drop in SBP over 6 months, vs. 9 mmHg in controls.

New ACC/AHA hypertension guidelines empasize risk assessment

AHA 2017 - Anaheim, CA, VS

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Prof. Clyde Yancy - Chicago, IL, USA
Prof. Clyde Yancy summarizes the most important new recommendations, starting with a new definition of hypertension, the need for a risk conversation and implications for therapy.

AHA 2017 Prof. Clyde Yancy summarizes the most important new recommendations, starting with a new definition of hypertension, the need for a risk conversation and implications for therapy.

Good BP measurement depends more on appropriate technique than on absence of staff

AHA 2017 - Anaheim, CA, USA

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Karen Johnson - Memphis, TN, USA
in the SPRINT study, BP was not always measured in absence of a physician or nurse. A posthoc survey investigated whether this affected the findings of the study.

AHA 2017 In the SPRINT study, BP was not always measured in absence of a physician or nurse. A posthoc survey investigated whether this affected the findings of the study.

Target for BP lowering differs between Europe and USA

AHA 2017 - Anaheim, CA, USA

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Prof. Clyde Yancy - Chicago, IL, USA
Although the broad statements remain intact, the target for BP lowering differs between Europe and USA. Prof Yancy explains the reasons for the differences in target of BP lowering between the 2 continents.

AHA 2017Although the broad statements remain intact, the target in BP lowering differs between Europe and USA; prof Yancy explains why.

Clinical outcomes and adverse effects comparable across various BP measurement methods in SPRINT

AHA 2017 - Anaheim, CA, USA

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Dr. Sripal Bangalore - NYU Langone, New York, NY, USA.
A lot of variation in BP measurement methods was seen in SPRINT, despite the protocol, but in 3/4 of sites patients were alone at least at some point during the BP reading.

AHA 2017 A lot of variation in BP measurement methods was seen in SPRINT, despite the protocol, but in 3/4 of sites patients were alone at least at some point during the BP reading.

New ACC/AHA Hypertension Guidelines: stress on accuracy BP measurement method and lifestyle changes ánd a new target

AHA 2017 - Anaheim, CA, USA

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Paul Whelton, MD (Tulane University, New Orleans, LA, USA
Paul Whelton, chair of the 2017 Hypertension Practice Guidelines, summarises the major changes as compared with the previous guideline.

AHA 2017 Paul Whelton, chair of the 2017 Hypertension Practice Guidelines, summarises the major changes as compared with the previous guideline.

BP lowering with endovascular baroreflex amplification in resistant hypertension: the CALM-FIM study

3' education - Aug. 29, 2017 - Dr. Wilko Spiering - UMCU
Dr. Wilko Spiering summarises the results of the CALM-FIM study, showing that endovascular baroreflex amplification with MobiusHD device lowers BP in resistant hypertension.

ESC 2017 Dr. Wilko Spiering summarises the results of the CALM-FIM study, showing that endovascular baroreflex amplification with MobiusHD device lowers BP in resistant hypertension.

Take home messages of the ESC congress for better hypertension treatment

3' education - Aug. 29, 2017 - Dr. Clyde Jancy - Northwestern University, Feinberg University, Chicago, IL, VS
Clyde Yancy summarises insights of studies presented at the ESC on managment of hypertension and associated CV risk, which can help understanding of how treatment can be improved.

ESC 2017 Clyde Yancy summarises insights of studies presented at the ESC on managment of hypertension and associated CV risk, which can help understanding of how treatment can be improved.

Well-conducted trial confirms principle that renal denervation can lower blood pressure

ESC 2017 - Barcelona

3' education - Aug. 29, 2017
The SPYRAL-HTN study showed encouraging results with renal denervation in a sham-controlled trial. Blood pressure was reduced in patients not requiring medication for their hypertension.

ESC 2017 The SPYRAL-HTN study showed encouraging results with renal denervation in a sham-controlled trial. Blood pressure was reduced in patients not requiring medication for their hypertension.

NSAID ibuprofen increases blood pressure significantly more than other selective COX2 inhibitors

ESC 2017 - Barcelona

3' education - Aug. 28, 2017
After seeing the PRECISION-ABPM results, Ruschitzka concludes that use of ibuprofen may need to be reconsidered in hypertensive arthritis, as its BP-increasing effect is stronger than that of celecoxib and naproxen.

ESC 2017 After seeing the PRECISION-ABPM results, Ruschitzka concludes that use of ibuprofen may need to be reconsidered in hypertensive arthritis, as its BP-increasing effect is stronger than that of celecoxib and naproxen.

E-counselling improves adherence in hypertensives

3' education - Mar. 21, 2017 - Dr. Rob Nolan, Toronto, ONT, Canada
 Dr. Rob Nolan presented the results of the double-blind randomised controlled REACH study, in which multi-medial e-counselling significantly improved antihypertensive therapy adherence, and it lowered blood pressure.

ACC 2017 Dr. Rob Nolan presented the results of the REACH study, in which multi-medial e-counselling significantly improved antihypertensive therapy adherence, and it lowered blood pressure.

Get involved in May Measurement Month!

3' education - Jan. 22, 2017 - London, United Kingdom - Prof. Neil R Poulter, MD (London, UK) - ISH President
Prof Neil R Poulter, MD calls for participation in May Measurement Month (MMM17)

Prof. Neil R Poulter, MD, ISH President, calls for participation in May Measurement Month (MMM17). MMM17 is a global Blood Pressure Awareness Campaign, incorporating World Hypertension Day.

How low to go with blood pressure: J-curve or not?

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Deepak L.Bhatt, MD, MPH (Boston, MA, USA)
Dr. Deepak L. Bhatt, MD, MPH, discusses the ongoing issue on how low to go with blood pressure - is there a J-curve or not?

Dr. Deepak L. Bhatt, MD, MPH, discusses the ongoing issue on how low to go with blood pressure - is there a J-curve or not? Lowering blood pressure too much may be associated with adverse CV outcomes, supporting the existence of a J-curve phenomenon.

To SPRINT or not to SPRINT to a lower blood pressure target?

10' education - Aug. 29, 2016 - ESC Rome, Italy - William C Cushman (Memphis, TN, USA) and Sverre E Kjeldsen (Oslo, Norway)
Two professors disagree on whether the results of the SPRINT trial on blood pressure lowering should influence new guidelines.

CSI ROME Nicolette van der Sande and Monique van Kleef critically discuss the SPRINT trial results with William Cushman and Sverre Kjeldsen. The professors disagree on whether these results should influence new guidelines.

Understanding Diabetic Kidney Disease: What are the best options for clinical management?

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - Per-Henrik Groop, MD – University of Helsinki, Helsinki, Finland

Dr. Per-Henrik Groop outlines that diabetic kidney disease is common and associated with a grim prognosis. Optimal glucose control is central to limiting the risk of renal complications. Newer antidiabetic drugs can play a welcome role to optimally treat these patients.

BP-lowering medication should not be used in normotensive primary prevention population at intermediate CV risk

10' education - May 10, 2016 - ACC 2016, Chicago, IL, USA - Eva Lonn (Hamilton, ONT, Canada)
##KEY_PHRASE##

BP-lowering medication should not be used in normotensive primary prevention population at intermediate CV risk

HOPE-3: Statin therapy works in everybody with intermediate-risk

3' education - Apr. 8, 2016 - Salim Yusuf MD, McMaster University, Hamilton, Ontario
##KEY_PHRASE##

ACC 2016 Prof. Salim Yusuf discusses the results of the HOPE-3 study, which indicates that statins are effective in all patients with intermediate CVD risk, whereas blood pressure lowering is only effective in hypertensive patients.

PARAMETER: heart failure agent to treat hypertension

3' education - Aug. 31, 2015 - ESC - Londen 2015 - Bryan Williams
##KEY_PHRASE##

ESC 2015 The PARAMETER study evaluated LCZ696, the agent that was found to be effective against heart failure in the PARADIGM-HF, in another population of patients with systolic hypertension. Prof. Bryan Williams discusses the results.

PARAMETER: heart failure agent to treat hypertension

3' education - Sep. 1, 2015 - ESC - Londen 2015 - Bryan Williams
##KEY_PHRASE##

ESC 2015 The PARAMETER study evaluated LCZ696, the agent that was found to be effective against heart failure in the PARADIGM-HF, in another population of patients with systolic hypertension.

PATHWAY-2: which agent can best treat therapy resistant hypertension?

3' education - Aug. 31, 2015 - ESC - Londen 2015 - Bryan Williams
##KEY_PHRASE##

ESC 2015 Prof. Bryan Williams (Londen) presented the PATHWAY-2, in which 3 different additional agentsto treat therapy resistant hypertension were compared. Spironalactone clearly performed better than the other two.

PARADIGM-HF: Rationale, results & implications

3' education - Dec. 11, 2014 - Chicago, Il, USA VBWG - John J McMurray
##KEY_PHRASE##

Prof John McMurray, Glasgow, explains the backgrounds of this trial with a novel ARNI and its potental implications for future Heart Failure management

CV Risk management in Russia

3' education - Dec. 3, 2014 - Moscow - Prof Andrey Susekov
##KEY_PHRASE##

Prof. Susekov, Moscow, with a brief update on current challenges to manage CVD in Russia, including some take home messages for Russian physicians

Innovating hypertension: targeting the underlying disease process

3' education - Sep. 8, 2014 - Barcelona - Prof Bryan Williams
##KEY_PHRASE##

Prof. Bryan Williams (London) urges the need for innovation to control systolic BP in our aging population

Innovating hypertension management beyond current therapies: What are the opportunities?

Prof Bryan Williams, London, United Kingdom

10' education - Sep. 6, 2014 - Snapshot 2014 - Prof. Bryan Williams, UCL, London, United Kingdom
##KEY_PHRASE##

Lecture held by Prof Bryan Williams, MD, UCL, London, United Kingdom on 'Innovating hypertension management beyond current therapies: What are the opportunities?' held during the PACE 2014 Snapshot session in Barcelona

Are new hypertension guidelines helpful for patients at high risk?

3' education - May 23, 2014 - CDMC Almaty - Dr Peter Meredith, Glasgow
##KEY_PHRASE##

Dr. Peter Meredith, Glasgow, UK, expresses his concerns about the potential impact of new hypertension guidelines on patients at increased CV risk and emphasises the importance of tight sustained blood pressure control.

Improving BP measurement for better hypertension management

3' education - Apr. 25, 2014 - CDMC Almaty - Prof Luis Ruilope, Madrid, Spain
##KEY_PHRASE##

Dr. Ruilope provides guidance for better measurement of blood pressure, for better management of this risk factor.

New British guidelines and risk calculator on CV Risk (JBS3)

3' education - Apr. 7, 2014 - ACC 2014 - Prof John E Deanfield
##KEY_PHRASE##

Prof. John E Deanfield highlights the key messages of JBS3: a new approach to CVD prevention, considering 'lifetime CV risk' and 'heart age'.

Update on therapy-resistant hypertension: Novel pharmacotherapy or renal denervation?

10' education - Sep. 14, 2013
##KEY_PHRASE##

As presented by prof Luis Ruilope, during the PACE 2013 SNAPSHOT session on August 31, 2013 in Amsterdam

Therapy resistant hypertension: novel pharmacotherapy or renal denervation?

3' education - Sep. 10, 2013 - Amsterdam, August 31, 2013 - Luis Ruilope
##KEY_PHRASE##

Prof. Luis Ruilope about current options to manage therapy resistant hypertension.

Blood Pressure: Does it matter how to lower it?

3' education - June 20, 2013 - CVRMC Kuala Lumpur - Prof. Peter Sever
##KEY_PHRASE##

Prof. Peter Sever, London, argues if all drug classes have the same effect, if blood pressure should be targeted aggressively, and if  BP variability is important.

The unmet need for controlling hypertension

3' education - June 17, 2013 - VBWG San Francisco - Dr. Domenic Sica
##KEY_PHRASE##

Dr. Domenic Sica (Virginia) reviews new developments in drug therapy and a range of new devices targeting the unmet need for controlling hypertension

Preview on new hypertension guidelines

3' education - May 8, 2013 - CDMC Hanoi - Prof Michael A Weber
##KEY_PHRASE##

Prof Michael Weber provides his expectations on the right level of blood pressure targets, the elderly patients and optimal therapies

New drugs and devices in development for hypertension

3' education - Apr. 18, 2013 - VBWG at ACC 2013 - Domenic Sica
##KEY_PHRASE##

Domenic Sica (Richmond, USA) provides an overview of new drugs and therapies in development for hypertension (aldosterone antagonists, renal denervation).

Renal denervation: New frontier in treating resistant hypertension

3' education - Dec. 11, 2012 - LA AHA 2012 - Dr Horst Sievert
##KEY_PHRASE##

Dr Horst Sievert, Germany, highlights current status of catheter based techniques to treat resistant hypertension.

Managing blood pressure: choosing the right strategy to meet BP targets

3' education - Oct. 28, 2011
##KEY_PHRASE##

Prof. Ruilope, Hopital 12 de Octubre, Madrid, Spain discusses recommendations in the management of hypertension and concurrent lifestyle modification.

RAS Blockade in the Real World: From Clinical Trial Data to Challenges in Daily Hypertension Management

3' education - Oct. 28, 2011
##KEY_PHRASE##

Prof. Kjeldsen, University of Oslo, Norway, on the inplementation of clinical trial results in hypertension into daily practice.

RAS Blockade in hypertension

3' education - July 22, 2011
##KEY_PHRASE##

Dr. Peter Meredith, Glasgow, UK, discusses structural differences between different ARB's used in the management of blood pressure.

Hypertension and diabetes

3' education - July 29, 2009
##KEY_PHRASE##

**Managing hypertension to protect the diabetic patient: When and how to intervene? **Prof. Tom MacDonald University of Dundee, United Kingdom